68Ga-FAPI PET/CT for the Detection of Adenoid Cystic Carcinoma(ACC)

Chinese Academy of Medical Sciences & Peking Union Medical College

Status: Unknown

Conditions: Metastatic Adenoid Cystic Carcinoma; 68Ga-FAPI PET/CT

Treatments: Drug: 68Ga-FAPI

Study type: Interventional

Funder types: Other

Identifiers

NCT05499936

PUMCHFAPI-ACC

Details and patient eligibility

About

This study was used to study the diagnostic value of 68Ga-FAPI, a novel fibroblast activating inhibitor, in metastatic adenoid cystic carcinoma（ACC）

Full description

68Ga-FAPI is a positron labeled inhibitor of fibroblast activating protein, which has been widely used in malignant tumor imaging in recent years. Adenoid cystic carcinoma (ACC) is a rare epithelial malignant tumor, which usually originates from salivary glands. Its typical characteristics are long clinical course and high rate of distant metastasis. The purpose of this study was to investigate the clinical value of 68Ga Fapi pet/ct in metastatic adenoid cystic carcinoma.

Enrollment: 30 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients with ACC suspected metastatic tumor,and being able to provide basic information and sign the written informed consent form

Exclusion criteria

• claustrophobia, pregnancy, breastfeeding, kidney or liver failure, inability to fulfill the study

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

30 participants in 1 patient group

68Ga-FAPI PET/CT

Experimental group

Description:

Imaging was performed 30-60 minutes after injection of 2-4mci 68Ga-FAPI tracer

Treatment:

Drug: 68Ga-FAPI